ALS Therapy to Be Pulled From the Market, Drugmaker Says

(MedPage Today) -- Amylyx Pharmaceuticals announced Thursday that it's removing its amyotrophic lateral sclerosis (ALS) drug sodium phenylbutyrate and taurursodiol (Relyvrio), also known as AMX0035, from U.S. and Canadian markets. The company...
Source: MedPage Today Public Health - Category: American Health Source Type: news